Printer Friendly

WYETH-AYERST LABORATORIES RESPONDS TO SENATE AGING COMMITTEE REPORT

 PHILADELPHIA, Feb. 3 /PRNewswire/ -- The following was released today by Wyeth-Ayerst Laboratories in response to a U.S. Senate Aging Committee report:
 Although American Home Products' (NYSE: AHP) pharmaceutical division Wyeth-Ayerst has not been identified as having reneged on any pricing commitments, we believe it is important to correct the are the facts about Wyeth-Ayerst products.
 Wyeth-Ayerst Laboratories will maintain its commitment with respect to its pricing policy for pharmaceuticals. The company recently committed to holding drug prices to the CPI for 1993. On March 5, 1992, AHP told security analysts that drug price increases were expected to be at 4 percent or less for 1992. At that time, we assumed that the CPI would approach the 3 to 4 percent range. In fact, our price increases for 1992 were held to 3.7 percent for all of our pharmaceutical products -- not significantly different from the CPI of 3 percent. these figures have been reviewed and verified by our Certified Public Accountants, Arthur Andersen & Co. The average price for a Wyeth-Ayerst prescription continues to be below the industry average, and this average includes generics.
 Wyeth-Ayerst's total rebates/discounts and humanitarian aid runs into hundreds of millions of dollars per year. The company continues to participate in the Medicaid Drug Rebate Program and will provide rebates or discounts to a variety of government programs, such as Veterans Affairs, the Department of Defense, Public Health Service and state- funded pharmaceutical assistance programs. Wyeth-Ayerst Laboratories intends to continue to provide oral contraceptives at nominal prices to federally funded family planning clinics, Planned Parenthood and family planning centers.
 In spite of its very moderate price increases, AHP has increased its investment in new drug R&D to over half a billion dollars per year. Its ability to maintain and increase this investment is contingent upon an environment free of artificial price controls.
 Wyeth-Ayerst Laboratories is a major research-oriented pharmaceutical company with leading products in the areas of female health care, cardiovascular and metabolic diseases, central nervous system drugs, anti-inflammatory agents, and vaccines. Wyeth-Ayerst is also a leader and innovator in infant nutritionals.
 Here are the facts about Wyeth-Ayerst pricing.
 -- In 1992, total Wyeth-Ayerst price increases were 2.2 percent, while our pharmaceutical product prices increased by 3.7 percent.
 -- The eight products mentioned by the Committee represented less than 4 percent of our broad product line of over 250 products.
 -- Wyeth-Ayerst's average prescription price is below the industry average, and this average includes generic companies.
 -- Orudis prices were not raised in 1991, and in 1992 the actual price increase (after deals, discounts and rebates) was less than 2 percent.
 -- The price of Donnatal, a very small product representing less than 1/2 of 1 percent of Wyeth-Ayerst sales, increased by only 4 cents per day to the consumer in 1992.
 -- The actual price change for Isordil was 0 percent in 1992 and less than 4 percent in 1991.
 -- Premarin, which prevents osteoporosis, represents one of America's best health care values at 36 cents per day.
 -- Tenex remains a low cost and cost-effective treatment for hypertension.
 -- The actual 1992 Micro-K price increase (net of deals, discounts and rebates) was less than 2 percent.
 /delval/
 -0- 2/3/93
 /CONTACT: Audrey Ashby (media), 215-971-5823, or John R. Considine (investors), 212-878-6429, both of Wyeth-Ayerst Laboratories/
 (AHP)


CO: Wyeth-Ayerst Laboratories; American Home Products Corporation;
 U.S. Senate Aging Committee ST: Pennsylvania IN: MTC SU:


CC-MP -- PH015 -- 2348 02/03/93 11:37 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1993
Words:575
Previous Article:PHILADELPHIA ELECTRIC SHOWS CUSTOMERS HOW TO SAVE MONEY AT 1993 HOME SHOW
Next Article:RAILROADS ANNOUNCE POLICY ON HIGH SPEED RAIL
Topics:


Related Articles
WYETH-AYERST LABORATORIES ANNOUNCES VOLUNTARY RECALL OF CERTAIN LOTS OF EPINEPHRINE 1:1000 INJECTION
WYETH-AYERST LABORATORIES AND THE LIPOSOME COMPANY ANNOUNCE FLU VACCINE AGREEMENT
WYETH-AYERST AND PANLABS SIGN RESEARCH COLLABORATION
HASSAN NAMED GROUP V.P./GLOBAL PHARMACEUTICALS OF AMERICAN HOME PRODUCTS CORPORATION; ESSNER SUCCEEDS HASSAN AS WYETH-AYERST PRESIDENT
WYETH-AYERST STATEMENT ON PEPI TRIAL RESULTS
WYETH-AYERST STATEMENT ON PEPI TRIAL RESULTS; DATA PUBLISHED IN JANUARY 18 JAMA
WYETH-AYERST LABORATORIES AWARDS PHYSICIANS FOR SIGNIFICANT PROFESSIONAL ACHIEVEMENT
DURAMED SUBMITS SCIENTIFIC AND MEDICAL DATA TO FDA CONCLUDING DELTA(8,9) DHES HAS NO IMPACT ON SAFETY AND EFFICACY OF CONJUGATED ESTROGENS
FDA ADVISORY COMMITTEE RECOMMENDS CLEARANCE OF OBESITY DRUG
FDA Advisory Committee Concludes That First Vaccine for Use in Prevention of Rotavirus Gastroenteritis in Infants is Safe and Effective

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters